Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

ClinicalTrials.gov ID: NCT00669994

Public ClinicalTrials.gov record NCT00669994. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections

Study identification

NCT ID: NCT00669994
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bayer; Industry
Enrollment: 180 participants

Conditions and interventions

Conditions

Urinary Tract Infection

Interventions

Ciprofloxacin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 44 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2003
Primary completion: Not listed
Completion: Sep 30, 2003
Last update posted: Dec 18, 2014

2003

United States locations

U.S. sites: 31
U.S. states: 15
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Birmingham	Alabama	35242	—
Not listed	Pelham	Alabama	35124	—
Not listed	Phoenix	Arizona	85023	—
Not listed	Laguna Hills	California	92653	—
Not listed	Long Beach	California	90806	—
Not listed	San Diego	California	92182-4701	—
Not listed	San Luis Obispo	California	93401	—
Not listed	San Mateo	California	94403-4398	—
Not listed	Sylmar	California	91342	—
Not listed	Yorba Linda	California	92886	—
Not listed	Avon	Connecticut	06001	—
Not listed	Clearwater	Florida	33761	—
Not listed	Pembroke Pines	Florida	33024	—
Not listed	Evansville	Indiana	47714	—
Not listed	Milford	Massachusetts	01757	—
Not listed	Royal Oak	Michigan	48073-6769	—
Not listed	Elizabeth	New Jersey	07202-3672	—
Not listed	Holmdel	New Jersey	07733	—
Not listed	Camillus	New York	13031	—
Not listed	Beaver	Pennsylvania	15009	—
Not listed	Feasterville	Pennsylvania	19053	—
Not listed	Hatboro	Pennsylvania	19040	—
Not listed	Summerville	South Carolina	29485	—
Not listed	San Antonio	Texas	78209	—
Not listed	Murray	Utah	84107	—
Not listed	Salt Lake City	Utah	84102	—
Not listed	Salt Lake City	Utah	84109	—
Not listed	Salt Lake City	Utah	84121	—
Not listed	West Jordan	Utah	84088	—
Not listed	Madison	Wisconsin	53715	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00669994, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2014 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00669994 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →